Subject(s)
Acetazolamide , Altitude , Carbonic Anhydrase Inhibitors/adverse effects , Exercise , Exercise Therapy , HumansABSTRACT
The novel heavy/light chain (HLC) assay was used for the detection and measurement of monoclonal immunoglobulins, response evaluation and prognostication. This test allows identification and quantification of the different light chain types of each immunoglobulin class (for example, IgGκ and IgGλ) and enables calculation of ratios of monoclonal/polyclonal immunoglobulin (HLC ratio). Sequential sera of 156 patients with IgG or IgA myeloma started on first-line therapy and followed for a median of 46.1 months were analyzed. Results were compared with those obtained with conventional techniques (serum protein electrophoresis (SPEP), immunofixation electrophoresis (IFE), nephelometry (NEPH), and the free light chain test (FLC)). Our data show that the HLC assay allowed quantification of monoclonal proteins not accurately measurable by SPEP or NEPH. When both HLC and FLC testing were applied for response assessment, clonal excess was noted in 14/31 patients with complete response (CR). HLC ratio indicated presence of disease in 8/31 patients who achieved CR and, in sequential studies indicated evolving relapse in three patients before IFE became positive. Highly abnormal HLC ratios at presentation were significantly associated with shorter overall survival (40.5 months vs median not reached, P=0.016). Multivariate analysis revealed HLC ratio (P=0.03) and ß(2)-microglobulin (P<0.01) as independent risk factors for survival.
Subject(s)
Biomarkers/blood , Immunoglobulin Heavy Chains/blood , Immunoglobulin Light Chains/blood , Monitoring, Physiologic , Multiple Myeloma/blood , Neoplasm, Residual/diagnosis , Paraproteinemias/diagnosis , Adult , Aged , Aged, 80 and over , Blood Protein Electrophoresis , Female , Follow-Up Studies , Humans , Immunoelectrophoresis , Immunoglobulin Isotypes/blood , Immunophenotyping , Male , Middle Aged , Multiple Myeloma/therapy , Neoplasm, Residual/blood , Neoplasm, Residual/mortality , Paraproteinemias/blood , Paraproteinemias/mortality , Prognosis , Risk Factors , Survival RateABSTRACT
We hypothesized that the suppression of uninvolved immunoglobulin in monoclonal gammopathy of undetermined significance (MGUS) as detected by suppression of the isotype-specific heavy and light chain (HLC-pair suppression) increases the risk of progression to malignancy. This approach required quantitation of individual heavy/light chains (for example, IgGλ in IgGκ MGUS patients). Of 1384 MGUS patients from Southeastern Minnesota seen at the Mayo Clinic from 1960 to 1994, baseline serum samples obtained within 30 days of diagnosis were available in 999 persons. We identified HLC-pair suppression in 27% of MGUS patient samples compared with 11% of patients with suppression of uninvolved IgG, IgA or IgM. HLC-pair suppression was a significant risk factor for progression (hazard ratio (HR), 2.3; 95% confidence interval (CI) 1.5-3.7; P<0.001). On multivariate analysis, HLC-pair suppression was an independent risk factor for progression to malignancy in combination with serum M-spike size, heavy chain isotype and free light chain ratio (HR, 1.8; 95% CI, 1.1-3.00; P=0.018). The finding that HLC-pair suppression predicts progression in MGUS and occurs several years before malignant transformation has implications for myeloma biology.
Subject(s)
Biomarkers/blood , Immunoglobulin Heavy Chains/blood , Immunoglobulin Light Chains/blood , Monoclonal Gammopathy of Undetermined Significance/blood , Adolescent , Adult , Aged , Child , Child, Preschool , Disease Progression , Female , Humans , Immunoglobulin Heavy Chains/chemistry , Immunoglobulin Isotypes/blood , Immunoglobulin Light Chains/chemistry , Immunophenotyping , Infant , Infant, Newborn , Male , Middle Aged , Monoclonal Gammopathy of Undetermined Significance/mortality , Monoclonal Gammopathy of Undetermined Significance/therapy , Prognosis , Risk Factors , Survival Rate , Young AdultABSTRACT
Elevated immunoglobulin free light chain (FLC) level and abnormal FLC ratio are commonly seen in multiple myeloma (MM) and have prognostic implications. We hypothesized that presence of immunoglobin heavy chain (IgH) translocations leads to unbalanced production of light chains and more extreme abnormalities of FLC, and may explain the prognostic value of FLC. We studied 314 patients with newly diagnosed MM enrolled in a phase III trial, in whom results of fluorescence in situ hybridization testing and data on serum FLC levels were available. Cytogenetic analyses and FLC estimates were performed on stored samples and results were correlated with clinical data. The median ratio (FLC ratio) and the absolute difference (FLC diff) between the involved and uninvolved FLC were higher among those with IgH translocations, especially t(14;16). In multivariate analysis, the prognostic value of FLC estimates on progression-free and overall survival were independent of high-risk IgH translocations t(4;14) and t(14;16). A combination of the risk factors; either abnormal FLC estimate and/or the presence of high-risk IgH translocation, achieved better prognostic stratification. We conclude that patients with IgH translocations have higher FLC levels and abnormal ratios, but the prognostic effect of FLC is only partially explained by translocation status. A system including both these risk factors allows better prediction of outcome.
Subject(s)
Immunoglobulin Heavy Chains/genetics , Immunoglobulin Light Chains/blood , Multiple Myeloma/genetics , Translocation, Genetic , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Humans , In Situ Hybridization, Fluorescence , Multiple Myeloma/blood , Multiple Myeloma/drug therapy , Prognosis , Survival AnalysisABSTRACT
The effects of submaximal and maximal exercise on cerebral perfusion were assessed using a portable, recumbent cycle ergometer in nine unacclimatized subjects ascending to 5,260 m. At 150 m, mean (SD) cerebral oxygenation (rSO2%) increased during submaximal exercise from 68.4 (SD 2.1) to 70.9 (SD 3.8) (P < 0.0001) and at maximal oxygen uptake (.VO2(max)) to 69.8 (SD 3.1) (P < 0.02). In contrast, at each of the high altitudes studied, rSO2 was reduced during submaximal exercise from 66.2 (SD 2.5) to 62.6 (SD 2.1) at 3,610 m (P < 0.0001), 63.0 (SD 2.1) to 58.9 (SD 2.1) at 4,750 m (P < 0.0001), and 62.4 (SD 3.6) to 61.2 (SD 3.9) at 5,260 m (P < 0.01), and at .VO2(max) to 61.2 (SD 3.3) at 3,610 m (P < 0.0001), to 59.4 (SD 2.6) at 4,750 m (P < 0.0001), and to 58.0 (SD 3.0) at 5,260 m (P < 0.0001). Cerebrovascular resistance tended to fall during submaximal exercise (P = not significant) and rise at .VO2(max), following the changes in arterial oxygen saturation and end-tidal CO(2). Cerebral oxygen delivery was maintained during submaximal exercise at 150 m with a nonsignificant fall at .VO2(max), but at high altitude peaked at 30% of .VO2(max) and then fell progressively at higher levels of exercise. The fall in rSO2 and oxygen delivery during exercise may limit exercise at altitude and is likely to contribute to the problems of acute mountain sickness and high-altitude cerebral edema.
Subject(s)
Altitude , Brain/blood supply , Brain/physiology , Cerebrovascular Circulation/physiology , Oxygen Consumption/physiology , Physical Endurance/physiology , Physical Exertion/physiology , Adult , Aged , Exercise Test , Female , Humans , Male , Middle Aged , Vascular Resistance/physiologyABSTRACT
Monoclonal immunoglobulin free light chains (FLC) are found in the serum and urine of patients with a number of B-cell proliferative disorders, including multiple myeloma. Automated immunoassays, which can measure FLC in serum, are useful for the diagnosis and monitoring of light chain (AL) amyloidosis, Bence Jones myeloma and non-secretory myeloma patients. We report the results of a study investigating the utility of serum FLC measurements in myeloma patients producing monoclonal intact immunoglobulin proteins. FLC concentrations were measured in presentation sera from 493 multiple myeloma patients with monoclonal, intact immunoglobulin proteins. Serial samples were assayed from 17 of these patients and the FLC measurements were compared with other disease markers. Serum FLC concentrations were abnormal in 96% of patients at presentation. FLC concentrations fell more rapidly in response to treatment than intact immunoglobulin G (IgG) and showed greater concordance with serum beta2 microglobulin concentrations and bone marrow plasma cell assessments. It was concluded that serum FLC assays could be used to follow the disease course in nearly all multiple myeloma patients. In addition, because of their short serum half-life, changes in serum FLC concentrations provide a rapid indication of the response to treatment.
Subject(s)
Immunoglobulin Light Chains/blood , Multiple Myeloma/blood , Biomarkers/blood , Half-Life , Humans , Immunoglobulin Light Chains/metabolism , Multiple Myeloma/drug therapy , Nephelometry and Turbidimetry , Recurrence , Reference Values , Retrospective StudiesABSTRACT
Parathyroid carcinoma is a rare cause of primary hyperparathyroidism, and the efficacy of medical therapy and chemo- and radiotherapy is poor in recurrent or metastatic disease. We report the first case of PTH immunization in which tumor shrinkage accompanied hormonal, biochemical, and clinical improvements in a patient with metastatic parathyroid carcinoma.A 50-yr-old woman with refractory parathyroid carcinoma and pulmonary metastases was immunized eight times between February 2001 and December 2003 with bovine and modified human PTH fragments and intact human PTH, mixed with Freund's adjuvant. Total and ionized calcium and PTH levels were assayed weekly for 6 months and regularly thereafter. Thoracic computed tomography scans were performed regularly. Antibodies to all PTH fragments were detected after two immunizations. Baseline PTH and total calcium were 213.0 ng/liter and 13.96 mg/dl, respectively, and remained elevated during the first three immunizations. From the fourth immunization onward, PTH and calcium decreased, and the patient's clinical condition improved markedly. PTH and calcium levels have remained controlled for more than 24 months, and the sizes (surface area) of pulmonary metastases decreased from baseline by 39-71%. This is the first evidence that PTH immunization not only can improve clinical, hormonal, and biochemical measures in parathyroid carcinoma but also has an antitumor effect.
Subject(s)
Carcinoma/secondary , Carcinoma/therapy , Immunotherapy , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Parathyroid Hormone/immunology , Parathyroid Neoplasms/pathology , Animals , Antibody Formation , Calcium/blood , Carcinoma/blood , Carcinoma/diagnostic imaging , Cattle , Female , Humans , Immunotherapy/adverse effects , Lung Neoplasms/blood , Lung Neoplasms/diagnostic imaging , Middle Aged , Parathyroid Hormone/blood , Peptide Fragments/immunology , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
We have described the expression of specific iodothyronine deiodinase mRNAs (using quantitative RT-PCR) and activities in normal human placentas throughout gestation and compared our findings to those in placentas from pregnancies affected by intrauterine growth restriction (IUGR). The predominant deiodinase expressed in placenta was type III (D3); type II (D2) was also present. In general terms, the activities of the enzymes D2 and D3 (and mRNAs encoding these enzymes) were higher earlier in gestation (<28 wk) than at term and displayed an inverse relationship with the duration of gestation (P < 0.05). Comparison of the relative expressions of mRNAs encoding D2 and D3 as well as their activities in placentas associated with IUGR (early and late gestational groups) with findings from normal placentas of similar gestational ages revealed no significant differences. Immunolocalization of D2 and D3 in syncytiotrophoblast (including syncytial sprouts) and cytotrophoblast of human placentas was demonstrated at both early and late gestation. Treatment of primary cultures of term cytotrophoblast cells in vitro with increasing doses of T(3) (1, 10, and 100 nM) resulted in increased expression of mRNAs encoding both D2 and D3 at 100-nM concentrations (P < 0.01) compared with control. Experiments with JEG-3 choriocarcinoma cells demonstrated a similar effect on D3 mRNA at 10 and 100 nM T(3) (P < 0.01). The demonstrated changes in iodothyronine deiodinase expression in the placenta across pregnancy are likely to contribute to regulation of the thyroid hormone supply to the developing fetus. The lack of difference in deiodinase expression in normal placentas and those found in IUGR argues against placental deiodinases being responsible for the hypothyroxemia in circulating fetal thyroid hormones observed in this condition.
Subject(s)
Fetal Growth Retardation/enzymology , Fetal Growth Retardation/genetics , Gene Expression Regulation, Enzymologic/genetics , Iodide Peroxidase/biosynthesis , Iodide Peroxidase/genetics , Placenta/enzymology , Adult , Choriocarcinoma/enzymology , Female , Humans , Immunohistochemistry , Isoenzymes/biosynthesis , Isoenzymes/genetics , Placenta/cytology , Pregnancy , RNA, Messenger/biosynthesis , Reference Values , Reverse Transcriptase Polymerase Chain Reaction , Triiodothyronine/metabolism , Trophoblasts/enzymology , Tumor Cells, Cultured , Uterine Neoplasms/enzymologyABSTRACT
Differentiated thyroid cancers are the most common endocrine cancers, but there are no reliable molecular markers of prognosis. Pituitary tumor transforming gene (PTTG) plays several potential roles in tumor initiation and progression, including regulating mitosis and stimulating expression of fibroblast growth factor (FGF)-2. Increased expression of PTTG has been demonstrated in follicular thyroid lesions, and expression of this oncogene has been identified as a potential prognostic marker in pituitary adenomas and colon carcinomas. We assessed the expression of PTTG and FGF-2 and its receptor FGF-R-1 in 27 differentiated thyroid cancers, and we compared this with expression in 11 normal thyroids, 25 multinodular goiters, and 13 Graves' disease specimens. We also examined the relationship between gene expression and clinical markers of tumor behavior. PTTG and FGF-2 were overexpressed in thyroid carcinomas (9.5-fold increase, P = 0.003, and 5.0-fold increase, P < 0.001, respectively) compared with normal thyroid. Increased FGF-2 mRNA expression was independently associated with the findings of lymph node invasion (R(2) = 0.71; P < 0.001) and distant metastasis (R(2) = 0.55; P = 0.009) at tumor presentation, after taking into account known prognostic factors such as age and gender of the patient and size and type of the tumor. High PTTG expression was independently associated with tumor recurrence (R(2) = 0.64; P = 0.003). We conclude that PTTG and FGF-2 expression are potential prognostic markers (and perhaps therapeutic targets) for differentiated thyroid cancer.
Subject(s)
Fibroblast Growth Factor 2/genetics , Gene Expression , Neoplasm Proteins/genetics , Thyroid Neoplasms/genetics , Adult , Biomarkers, Tumor/analysis , Female , Goiter, Nodular/metabolism , Graves Disease/metabolism , Humans , Male , Neoplasm Recurrence, Local , Prognosis , Proliferating Cell Nuclear Antigen/genetics , RNA, Messenger/analysis , Receptors, Fibroblast Growth Factor/genetics , Securin , Thyroid Gland/chemistryABSTRACT
Primary systemic amyloidosis is a plasma cell dyscrasia characterized by the accumulation of excess free immunoglobulin light chains (FLCs) as amyloid. One of the diagnostic features of amyloidosis is the presence of circulating monoclonal FLCs in the serum and urine of the patients. The FLC usually is present in small amounts, and immunofixation is required for detection. A nephelometric method for quantitating FLCs in serum has been described using antibodies that recognize only FLC not bound to heavy chain. We describe a retrospective study using this quantitative FLC method for assessing monoclonal FLCs in 95 patients with amyloidosis. The sensitivity of nephelometric serum FLC measurements is particularly useful in patients with negative immunofixation results for serum, urine, or both. In addition, the FLC assay can be used for follow-up of patients with amyloidosis who have undergone stem cell transplantation.
Subject(s)
Amyloidosis , Biomarkers/blood , Immunoglobulin Light Chains/blood , Amyloid/metabolism , Amyloidosis/blood , Amyloidosis/diagnosis , Bone Marrow/metabolism , Bone Marrow/pathology , Humans , Immunoassay/methods , Nephelometry and Turbidimetry/methods , Retrospective Studies , Sensitivity and Specificity , Stem Cell Transplantation/methodsABSTRACT
The effects of gas mixtures comprising supplementary 3% carbon dioxide, 35% oxygen or a combination of 3% CO(2) plus 35% O(2) in ambient air have been compared on arterial blood gases, peripheral and cerebral oxygenation and middle cerebral artery velocity (MCAV) at 150 m and on acute exposure to 3459 m in 12 healthy subjects. Breathing 3% CO(2) or 35% O(2) increased arterial blood oxygen at both altitudes, and the CO(2)/O(2) combination resulted in the most marked rise. MCAV increased on ascent to 3459 m, increasing further with 3% CO(2) and decreasing with 35% O(2) at both altitudes. The CO(2)/O(2) combination resulted in an increase in MCAV at 150 m, but not at 3549 m. Cerebral regional oxygenation fell on ascent to 3459 m. Breathing 3% CO(2) or 35% O(2) increased cerebral oxygenation at both altitudes, and the CO(2)/O(2) combination resulted in the greatest rise at both altitudes. The combination also resulted in significant rises in cutaneous and muscle oxygenation at 3459 m. The key role of carbon dioxide in oxygenation at altitude is confirmed, and the importance of this gas for tissue oxygenation is demonstrated.
Subject(s)
Air , Altitude Sickness/physiopathology , Carbon Dioxide/pharmacology , Oxygen/pharmacology , Adult , Altitude , Altitude Sickness/blood , Blood Flow Velocity/drug effects , Blood Pressure/drug effects , Brain/metabolism , Carbon Dioxide/blood , Carbon Dioxide/physiology , Cerebral Arteries/physiopathology , Cerebrovascular Circulation/drug effects , Female , Heart Rate/drug effects , Humans , Male , Middle Aged , Muscle, Skeletal/metabolism , Oximetry/methods , Oxygen/blood , Oxygen Consumption/drug effects , Partial Pressure , Spectroscopy, Near-InfraredABSTRACT
Using sensitive, automated immunoassays, increased concentrations of either kappa or lambda free light chains (and abnormal kappa/lambda ratios) were detected in the sera of 19 of 28 patients with nonsecretory multiple myeloma. Four other patients had suppression of one or both light chains, and the remaining 5 sera had normal or raised free light-chain concentrations with substantially normal kappa/lambda ratios. Six of the patients with an elevated single free light chain, who were studied during follow-up, had changes in disease activity that were reflected by the changes in free light-chain concentrations. It is concluded that quantification of free light chains in serum should prove useful for the diagnosis and monitoring of many patients with nonsecretory myeloma.
Subject(s)
Immunoglobulin kappa-Chains/blood , Immunoglobulin lambda-Chains/blood , Multiple Myeloma/blood , Multiple Myeloma/immunology , Culture Media, Serum-Free , Humans , Immunoassay , Immunoglobulin kappa-Chains/immunology , Monitoring, PhysiologicABSTRACT
BACKGROUND: Bence Jones proteins or monoclonal immunoglobulin kappa and lambda free light chains (FLCs) are important markers for identifying and monitoring many patients with B-cell tumors. Automated immunoassays that measure FLCs in urine and serum have considerable clinical potential. METHODS: Sheep antibodies, specific for FLCs, were prepared by immunization with pure kappa and lambda molecules and then adsorbed extensively against whole immunoglobulins. The antibodies were conjugated onto latex particles and used to assay kappa and lambda FLCs on the Beckman IMMAGE protein analyzer. RESULTS: The unconjugated antibodies showed minimal cross-reactivity with intact immunoglobulins or other proteins. With latex-conjugated antibodies, kappa and lambda FLCs could be measured in normal sera and most normal urine samples. Patients with multiple myeloma had increased concentrations of the relevant serum FLC, whereas both FLCs were increased in the sera of patients with systemic lupus erythematosus. CONCLUSIONS: We developed sensitive, automated immunoassays for kappa and lambda FLC measurements in serum and urine that should facilitate the assessment of patients with light chain abnormalities.
Subject(s)
Immunoglobulin kappa-Chains/blood , Immunoglobulin kappa-Chains/urine , Immunoglobulin lambda-Chains/blood , Immunoglobulin lambda-Chains/urine , Animals , Antibody Specificity , Autoanalysis , Humans , Immunoassay , Immunoglobulin kappa-Chains/immunology , Immunoglobulin lambda-Chains/immunology , Latex , Lupus Erythematosus, Systemic/immunology , Multiple Myeloma/immunology , Nephelometry and Turbidimetry , Reference Standards , Sensitivity and Specificity , Sheep , Waldenstrom Macroglobulinemia/immunologySubject(s)
Antibodies, Neoplasm/immunology , Antigens, Neoplasm/immunology , Autoantibodies/immunology , Autoimmune Diseases of the Nervous System/immunology , DNA-Binding Proteins/immunology , Neoplasm Proteins/immunology , Nerve Tissue Proteins/immunology , Paraneoplastic Syndromes, Nervous System/immunology , RNA-Binding Proteins/immunology , Animals , Antibody Specificity , Autoantigens , Blotting, Western , Cell Nucleus/immunology , Cerebellum/immunology , ELAV Proteins , Female , Fluorescent Antibody Technique, Indirect , Haplorhini , Humans , Immunoenzyme Techniques , Male , Mice , Neoplasms/complications , Neoplasms/immunology , Neuro-Oncological Ventral Antigen , Neurons/immunology , Paraneoplastic Cerebellar Degeneration/etiology , Paraneoplastic Cerebellar Degeneration/immunology , Paraneoplastic Syndromes, Nervous System/etiology , Purkinje Cells/immunology , Rats , Species SpecificityABSTRACT
MICA is an acronym for mirror image complementary antibodies. The MICA system is a novel, avidin-free immunohistochemical detection system that provides a significant increase in sensitivity compared to traditional immunodetection systems. The principle of the system is the alternate and sequential application of mutually attractive polyclonal antibodies to form a large complex of antibodies which can cross-link tissue-bound primary antibodies. Peroxidase conjugated to the constituent antibodies permits signal generation. The formed peroxidase-containing complex is very stable and, by cross-linking tissue-bound primary antibodies, possesses high avidity for the target antigens, thereby producing high immunohistochemical sensitivity.
Subject(s)
Immunohistochemistry/methods , Animals , Antibody Affinity , Antigen-Antibody Complex , Humans , Immune Sera , Immunoenzyme Techniques , Sensitivity and SpecificityABSTRACT
The secosteroid hormone 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) plays a vital role in calcium metabolism, tissue differentiation, and normal bone growth. Biosynthesis of 1,25(OH)2D3 is catalyzed by the mitochondrial cytochrome P450 enzyme 25-hydroxyvitamin D3 1alpha-hydroxylase (1alpha-hydroxylase). Although activity of this enzyme has been described in several tissues, the kidneys are recognized to be the principal site of 1,25(OH)2D3 production. To date, enzyme activity studies using vitamin D-deficient animals have suggested that 1alpha-hydroxylase is expressed exclusively in proximal convoluted tubules. With the recent cloning of 1alpha-hydroxylase, specific cRNA probes and in-house polyclonal antiserum have been used to determine the distribution of 1alpha-hydroxylase along the human nephron. Immunohistochemistry and in situ hybridization studies indicated strong expression of 1alpha-hydroxylase protein and mRNA in the distal convoluted tubule, the cortical and medullary part of the collecting ducts, and the papillary epithelia. Lower expression was observed along the thick ascending limb of the loop of Henle and Bowman's capsule. Weaker and more variable expression of 1alpha-hydroxylase protein and mRNA was seen in proximal convoluted tubules, and no expression was observed in glomeruli or vascular structures. These data show for the first time the distribution of alpha1-hydroxylase expression in normal human kidney. In contrast to earlier enzyme activity studies conducted in vitamin D-deficient animals, our data indicate that the distal nephron is the predominant site of 1alpha-hydroxylase expression under conditions of vitamin D sufficiency.
Subject(s)
25-Hydroxyvitamin D3 1-alpha-Hydroxylase/genetics , 25-Hydroxyvitamin D3 1-alpha-Hydroxylase/metabolism , Kidney/enzymology , Adult , Animals , Base Sequence , Cells, Cultured , DNA Primers/genetics , Gene Expression , Humans , Immunohistochemistry , In Situ Hybridization , Nephrons/enzymology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Tissue Distribution , Vitamin D Deficiency/enzymology , Vitamin D Deficiency/geneticsABSTRACT
BACKGROUND: Patients with parathyroid tumours can develop extreme hypercalcaemia and osteitis fibrosa cystica. Clinical features result from the action of parathyroid hormone (PTH) on bone receptors. Because this hormone is produced in microgram quantities, inhibition of its metabolic effects with potent PTH antibodies should be possible. We tested whether an immunisation with synthetic human and bovine PTH peptides could stimulate autoantibodies against PTH. METHODS: A patient with metastatic parathyroid carcinoma in the lungs and pleura developed severe bone disease and extreme hypercalcaemia that proved resistant to conventional therapy. She was immunised with 200 microg human and bovine PTH peptides and 50 microg human PTH. Booster doses were also given at 4 weeks and 11 weeks. The patient was then seen every week. FINDINGS: Antibodies against PTH were produced within 4 weeks of initial immunisation and titres increased with repeated doses of immunogens. Total serum calcium concentrations, which had ranged from 3.5 mmol/L to 4.2 mmol/L over the previous 18 months, fell to between 2.5 mmol/L and 3.0 mmol/L over 6 months of therapy. This fall was accompanied by striking clinical improvement. INTERPRETATION: We believe this is the first use of immunotherapy to control remote, non-metastatic complications of malignant disease. B-cell tolerance to human PTH was broken by immunisation with PTH peptides in adjuvant. This therapeutic approach could be used to control excess hormone production in several types of endocrine tumour and may have applications in other diseases.